Influenza Dual Path Platform Assays

The Centers for Disease Control and Prevention (CDC), National Center for Immunization & Respiratory Diseases (NCIRD), Influenza Division intends to procure Influenza Dual Path Platform (DPP) prototype assays on a sole source basis from Chembio Diagnostics, Medford, New York 11763. The North American Industry Classification System (NAICS) code for this requirement is 325414, Biological Product (except Diagnostic) Manufacturing, and the Small Business Standard Size is 500 employees. The Government intends to procure from only one source under the authority of FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. The vendor developed the DPP platform assay technology and holds the patent rights. This is not a request for competitive proposals, nor is a solicitation available. Any firm that believes it can furnish the items described above is encouraged to give written notification to the Contracting Officer within 15 days of the date of this synopsis. Supporting evidence must be furnished in sufficient detail to demonstrate the ability to comply with the above requirements. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. A determination by the Government not to compete this proposed action, based on responses to this notice, is solely within the discretion of the Government.